Exelixis | EXEL - Debt


Exelixis reported $169.54M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 52.19M 2.62M Dec/2025
Agios Pharmaceuticals USD 40.21M 4.31M Dec/2025
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Amgen USD 54.6B 17M Dec/2025
AstraZeneca USD 33.92B 4.3B Mar/2026
Bayer EUR 36.45B 2.93B Dec/2025
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Cytokinetics USD 1.29B 4.48M Mar/2026
Eisai JPY 236.67B 49.14B Sep/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Exelixis USD 169.54M 3.5M Mar/2026
Genmab DKK 148M 5M Jun/2025
Glaxosmithkline GBP 17.75B 396M Sep/2025
Incyte USD 39.43M 982K Mar/2026
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
MacroGenics USD 37.01M 238K Sep/2025
Merck USD 49.34B 7.97B Dec/2025
Moderna USD 1.31B 571M Dec/2025
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 47B 11.62B Mar/2026
Pfizer USD 63.73B 231M Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Sanofi EUR 21.76B 530M Sep/2025
Takeda JPY 4.85T 208B Dec/2025
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Xencor USD 187.75M 118.48M Dec/2025